- Home
- PRQR vs REFI Comparison
PRQR vs REFI Comparison
Compare PRQR & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- REFI
- Stock Information
- Founded
- PRQR 2012
- REFI 2021
- Country
- PRQR Netherlands
- REFI United States
- Employees
- PRQR N/A
- REFI N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- PRQR Health Care
- REFI Real Estate
- Exchange
- PRQR Nasdaq
- REFI Nasdaq
- Market Cap
- PRQR 309.5M
- REFI 291.9M
- IPO Year
- PRQR 2014
- REFI 2021
- Fundamental
- Price
- PRQR $1.55
- REFI $14.85
- Analyst Decision
- PRQR Strong Buy
- REFI Strong Buy
- Analyst Count
- PRQR 6
- REFI 3
- Target Price
- PRQR $9.00
- REFI $20.00
- AVG Volume (30 Days)
- PRQR 678.2K
- REFI 112.2K
- Earning Date
- PRQR 05-08-2025
- REFI 05-07-2025
- Dividend Yield
- PRQR N/A
- REFI 13.87%
- EPS Growth
- PRQR N/A
- REFI N/A
- EPS
- PRQR N/A
- REFI 1.88
- Revenue
- PRQR $21,212,711.00
- REFI $56,790,054.00
- Revenue This Year
- PRQR $6.44
- REFI $17.87
- Revenue Next Year
- PRQR N/A
- REFI N/A
- P/E Ratio
- PRQR N/A
- REFI $7.90
- Revenue Growth
- PRQR 85.91
- REFI 4.68
- 52 Week Low
- PRQR $1.07
- REFI $12.76
- 52 Week High
- PRQR $4.62
- REFI $16.47
- Technical
- Relative Strength Index (RSI)
- PRQR 50.51
- REFI 59.49
- Support Level
- PRQR $1.50
- REFI $14.50
- Resistance Level
- PRQR $2.02
- REFI $14.81
- Average True Range (ATR)
- PRQR 0.17
- REFI 0.27
- MACD
- PRQR 0.03
- REFI 0.12
- Stochastic Oscillator
- PRQR 48.04
- REFI 93.44
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.